US2022162171A1PendingUtilityA1

Compositions and methods for the treatment of gastrointestinal polyps

Assignee: CELLIX BIO PRIVATE LTDPriority: Nov 11, 2016Filed: Dec 2, 2021Published: May 26, 2022
Est. expiryNov 11, 2036(~10.3 yrs left)· nominal 20-yr term from priority
Inventors:Mahesh Kandula
C07C 2602/08A61P 1/00C07C 317/44A61K 31/232A61P 29/00C07C 229/58A61K 31/27C07C 229/62A61P 1/04C07D 239/94C07C 229/30C07C 219/20C07C 219/32C07C 229/36A61K 31/216
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound of Formula I: 
       
         
           
           
               
               
           
         
         and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof; 
         wherein 
         R 1 , R 3 , and R 5  each independently represents NULL, 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         R 2 , R 4 , and R 6  each independently represents 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         n is independently 1, 2, 3, 4 or 5; 
         a is independently 2, 3 or 7; 
         each b is independently 3, 5 or 6; 
         e is independently 1, 2 or 6; 
         c and d are each independently H, D, —OH, —OD, C 1 -C 6 -alkyl, —NH 2  or —COCH 3 . 
       
     
     
         2 . A pharmaceutical composition comprising a compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration. 
     
     
         4 . The pharmaceutical composition of  claim 3  formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation. 
     
     
         5 . A method of treating at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease comprising:
 administering the compound of  claim 1  to patient suffering from at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease, wherein said compound of  claim 1  is selected from the group consisting of   
       
         
           
           
               
               
           
         
       
     
     
         6 . A compound of  claim 1  selected from the group consisting of: 
     
     
         7 . A pharmaceutical composition comprising a compound of  claim 6 , and a pharmaceutically acceptable carrier. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration. 
     
     
         9 . The pharmaceutical composition of  claim 8  formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation.

Join the waitlist — get patent alerts

Track US2022162171A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.